organisation · intermediate · partly written
Pikman Lab (Dana-Farber Cancer Institute)
A pediatric leukemia research group at Dana-Farber Cancer Institute that works on matched targeted therapy and on one-carbon metabolism as a drug target.
Also called: Pikman lab, Yana Pikman lab
What the lab says it is doing
The lab's own research page names two projects. One is precision medicine: validating mutations in pediatric AML and ALL models, targeting RAS signalling and pairing MAPK-pathway drugs with other agents. The other is the mitochondrial one-carbon folate pathway in AML and ALL. These are the lab's own statements. 1
Reported, not yet replicated
Who leads it and where it sits more
The principal investigator is Yana Pikman, MD, printed on the Dana-Farber physician page as Assistant Professor of Pediatrics at Harvard Medical School and Co-Director of the Hematologic Malignancy Program of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center. No other investigator named Pikman at Dana-Farber appeared in searches; the institute directory was not read exhaustively. 2
Reported, not yet replicated
What the published record shows more
The lab's led papers are first-author work on MTHFD2 in AML (2016), on SHMT1/2 in T-ALL (2022) and on the LEAP matched-therapy study (2021). In the 2026 menin plus MEK paper she is an author, and the combination lowered leukemia burden in patient-derived mouse models without a survival gain beyond the menin inhibitor alone. The RAS and MAPK programme the lab names has no first- or last-author MEK research paper in the record read. 3456
Reported, not yet replicated
Clinical translation: plan against result more
Registry NCT02670525 (sponsor Dana-Farber) planned a feasibility test: the rate of actionable alterations, feasible if at least 13%. The posted result is 77% of 101 analysed relapsed or refractory patients (90% confidence interval 69 to 84). The registered outcomes contain no response, remission or survival measure, so this is a feasibility result, not a benefit result. 7
Established
Still open here
- What happened to the 338 patients in the matched-therapy registry? Outcomes for treated patients are not posted.
- Which grant supports the lab after the K08 ended in January 2023? None was found with Pikman as principal investigator.
- Has any group outside the lab reproduced the SHMT1/2 or MTHFD2 results in leukemia? None was found.
Not yet written: Kind, URL, Offers, Caveats.
Linked from
Sources
- Pikman Lab: research (Dana-Farber). (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- Yana Pikman, MD (Dana-Farber physician profile). (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- Pikman Y, et al. Targeting MTHFD2 in acute myeloid leukemia (J Exp Med 2016). (2016). paper; opened 2026-11-17 all records citing this
- Pikman Y, et al. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy (Leukemia 2022). (2022). paper; opened 2026-11-17 all records citing this
- Pikman Y, et al. Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium (Cancer Discovery 2021). (2021). paper; opened 2026-11-17 all records citing this
- Menin inhibitor plus MEK inhibitor in KMT2A-rearranged RAS-mutant AML (Blood Advances 2026; descriptive title, exact title not copied). (2026). paper; opened 2026-11-17 all records citing this
- ClinicalTrials.gov NCT02670525: Matched Targeted Therapy for High-Risk Leukemias and MDS. (2026). database, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (4)
This record has been changed 4 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/organisations/pikman-lab-dana-farber.json